Table 2.
ARs antagonists generally stabilize GABAA receptors microtransplanted to oocytes from dysplastic neocortices
| Drug treatment (dose) | Tested oocytes (frogs) [patients] | IGABA, %, before treatment (n) | IGABA, %, after treatment | P |
|---|---|---|---|---|
| PFCD | ||||
| ANR82 (100 nM) [A2A antagonist] | 41 (6) [6–9] | 62.1 ± 4.8 (6) | 47.5 ± 2.4 | <0.01 |
| 45.8 ± 2.1 (27) | 60.9 ± 1.5 | <0.001 | ||
| ANR94 (100 nM) [A2A antagonist] | 20 (4) [6 and 7] | 46.5 ± 2.0 (10) | 55.5 ± 2.4 | <0.001 |
| ANR152 (100 nM) [A2A & A1 antagonist] | 12 (2) [6] | 51.7 ± 2.8 (8) | 69.0 ± 2.4 | <0.001 |
| ANR235 (100 nM) [A3 antagonist] | 24 (4) [6–8] | 48.5 ± 3.3 (24)* | 50.7 ± 2.9* | >0.5 |
| AFCD | ||||
| ANR82 (100 nM) [A2A antagonist] | 22 (3) [10 and 11] | 75 (1) | 66.7 | - |
| 51.6 ± 1.9 (18) | 69.4 ± 1.7 | <0.001 | ||
| ANR94 (100 nM) [A2A antagonist] | 23 (4) [10–12] | 56.2 ± 2.2 (13) | 72.6 ± 2.8 | <0.001 |
| ANR152 (100 nM) [A1 and A2A antagonist] | 12 (2) [10 and 12] | 51.7 ± 2.0 (9) | 64.5 ± 2.7 | <0.001 |
| ANR152 (10 nM) [A2A antagonist] | 11 (2) [12] | 59.7 ± 2.3 (9) | 67.2 ± 2.0 | <0.001 |
| Mix DPCPX (30 nM) [A1 antagonist] | 10 (2) [10] | 54.3 ± 4 (7) | 68.5 ± 4 | <0.001 |
| ANR152 (10 nM) [A2A antagonist] | 61.2 + 4 (3) | 58.8 ± 4* | >0.5 | |
| DPCPX (30 nM) [A1 antagonist] | 3 (1) [10] | 57.1 ± 1.3 (3) | 57.2 ± 0.7 | >.5 |
| ANR235 (100 nM) [A3 antagonist] | 8 (2) [10 and 11] | 42.6 ± 5.7 (8)* | 34.6 ± 3.5* | >.5 |
n, number of oocytes responsive to AR antagonists. Set of cells in which rundown increases and n are in bold. IGABA (%) values represent the sixth IGABA amplitude normalized to the first of the rundown protocol.
*, Not significantly different.